How will HPV vaccines affect cervical cancer?
暂无分享,去创建一个
R. Roden | T. Wu | T.-C. Wu | Richard Roden
[1] D. McCance. Human Papillomaviruses and Cell Signaling , 2005, Science's STKE.
[2] D. Lowy,et al. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. , 1998, Virology.
[3] D. Parkin,et al. Usefulness of combining testing for p16 protein and human papillomavirus (HPV) in cervical carcinoma screening. , 2006, Gynecologic oncology.
[4] Drew M. Pardoll,et al. Vaccines: Spinning molecular immunology into successful immunotherapy , 2002, Nature Reviews Immunology.
[5] P. Lambert. Papillomavirus DNA replication , 1991, Journal of virology.
[6] M. Sapp,et al. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. , 2001, Virology.
[7] Geoffrey P Garnett,et al. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. , 2005, The Journal of infectious diseases.
[8] H. Hausen. Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.
[9] M. Lehtinen,et al. Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses , 2006, PLoS medicine.
[10] S. Akira,et al. Papillomavirus Capsid Mutation To Escape Dendritic Cell-Dependent Innate Immunity in Cervical Cancer , 2005, Journal of Virology.
[11] P. Rous,et al. THE PROGRESSION TO CARCINOMA OF VIRUS-INDUCED RABBIT PAPILLOMAS (SHOPE) , 1935, The Journal of experimental medicine.
[12] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[13] A. Giuliano,et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. , 2004, Vaccine.
[14] L. Brinton,et al. Evaluation of self-collected cervicovaginal cell samples for human papillomavirus testing by polymerase chain reaction. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] R. Schlegel,et al. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model. , 1994, Pathobiology : journal of immunopathology, molecular and cellular biology.
[16] D. Lowy,et al. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. , 2000, Virology.
[17] R. Schlegel,et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Lowy,et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. , 1996, Virology.
[19] I. Melo-Martín. The Promise of the Human Papillomavirus Vaccine Does Not Confer Immunity Against Ethical Reflection , 2006 .
[20] D. Lowy,et al. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. , 1989, The EMBO journal.
[21] R. Zimmerman. Ethical analysis of HPV vaccine policy options. , 2006, Vaccine.
[22] D. Solomon,et al. From Papanicolaou to Bethesda: The rationale for a new cervical cytologic classification , 1991, Obstetrics and gynecology.
[23] M. Li,et al. Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly , 1997, Journal of virology.
[24] C. Wheeler,et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. , 2004, Vaccine.
[25] C. Meyers,et al. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. , 1992, Science.
[26] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[27] S. Szu,et al. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. , 1995, The Journal of infectious diseases.
[28] N. Christensen,et al. Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein , 2002, Journal of Virology.
[29] Darren W. Henderson,et al. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins , 1994, Journal of virology.
[30] J. Dillner,et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. , 1999, The Journal of general virology.
[31] I. Frazer,et al. HPV6b virus like particles are potent immunogens without adjuvant in man. , 2000, Vaccine.
[32] C. Berkower,et al. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. , 2006, Vaccine.
[33] S. H. van der Burg,et al. Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.
[34] T. Sasagawa,et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6and Type 16 in fission yeast Schizosaccharomyces pombe , 1995 .
[35] P. De Grandi,et al. Improved Efficiency of a Salmonella-Based Vaccine against Human Papillomavirus Type 16 Virus-Like Particles Achieved by Using a Codon-Optimized Version of L1 , 2004, Journal of Virology.
[36] Xavier Castellsagué,et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.
[37] P. Dorian,et al. Canine Model , 2005 .
[38] Milton C Weinstein,et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. , 2004, Journal of the National Cancer Institute.
[39] Y. L. Lin,et al. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product , 1993, Journal of virology.
[40] C. Wheeler,et al. A controlled trial of a human papillomavirus type 16 vaccine. , 2002, The New England journal of medicine.
[41] D. Lowy,et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype , 1996, Journal of virology.
[42] D. Lowy,et al. Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles , 2004 .
[43] R. Garcea,et al. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles , 1993, Journal of virology.
[44] W. White,et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. , 2001, The Journal of infectious diseases.
[45] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[46] J. Palefsky. Human papillomavirus‐associated malignancies in HIV‐positive men and women , 1995, Current opinion in oncology.
[47] F. X. Bosch,et al. Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV-positive human cell lines , 1991, Journal of virology.
[48] K. Holmes,et al. Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women , 2006, The New England journal of medicine.
[49] Eto,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[50] R. Shope. IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS , 1937, The Journal of experimental medicine.
[51] R. Garcea,et al. Immunization with a Pentameric L1 Fusion Protein Protects against Papillomavirus Infection , 2001, Journal of Virology.
[52] D. Lowy,et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. , 2005, Vaccine.
[53] M. Grace,et al. Mechanisms of Human Papillomavirus-Induced Oncogenesis , 2004, Journal of Virology.
[54] J. Palefsky,et al. A review of human papillomavirus vaccines: from basic science to clinical trials. , 2003, Frontiers in bioscience : a journal and virtual library.
[55] D. Lowy,et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope , 1997, Journal of virology.
[56] H. Schild,et al. Cutting Edge: Priming of CTL by Transcutaneous Peptide Immunization with Imiquimod1 , 2005, The Journal of Immunology.
[57] R. Hoover,et al. Solid cancers after bone marrow transplantation. , 1997, The New England journal of medicine.
[58] Margaret E McLaughlin-Drubin,et al. Evidence for the coexistence of two genital HPV types within the same host cell in vitro. , 2004, Virology.
[59] M. Campo,et al. Studies on vaccination against papillomaviruses: a comparison of purified virus, tumour extract and transformed cells in prophylactic vaccination , 1990, Veterinary Record.
[60] Mark Schiffman,et al. The promise of global cervical-cancer prevention. , 2005, The New England journal of medicine.
[61] Claude Fauquet,et al. Classification of papillomaviruses. , 2004, Virology.
[62] David R. Scott,et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. , 2001, The Journal of infectious diseases.
[63] R. Karron,et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. , 2001, Journal of the National Cancer Institute.
[64] B. Evans,et al. Effect of local infection and oral contraception on immunoglobulin levels in cervical mucus , 1975, Infection and immunity.
[65] R. Reichman,et al. Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. , 1992, The Journal of infectious diseases.
[66] D. Lowy,et al. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. , 2001, Virology.
[67] D. Lowy,et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. , 1994, Journal of the National Cancer Institute.
[68] L Beardsley,et al. Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.
[69] N. Christensen,et al. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus , 1996, Journal of virology.
[70] R. Roden,et al. Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice , 1999, Journal of Virology.
[71] R. Schlegel,et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. , 1994, Virology.
[72] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[73] G. Garnett,et al. Public health paradoxes and the epidemiological impact of an HPV vaccine. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[74] C J L M Meijer,et al. The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.
[75] G. Grindlay,et al. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. , 1993, The Journal of general virology.
[76] W. White,et al. Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies , 1998, Journal of Virology.
[77] T. Wright,et al. Women's desired information about human papillomavirus , 2004, Cancer.
[78] C. Wheeler,et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2006, Obstetrics and gynecology.
[79] D. Lowy,et al. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition , 1996, Journal of virology.
[80] R. Reichman,et al. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. , 1994, The Journal of general virology.
[81] A. Roberts,et al. Intranasal Vaccination with a Recombinant Vesicular Stomatitis Virus Expressing Cottontail Rabbit Papillomavirus L1 Protein Provides Complete Protection against Papillomavirus-Induced Disease , 2002, Journal of Virology.
[82] J. Brandsma. Animal models of human-papillomavirus-associated oncogenesis. , 1994, Intervirology.
[83] Olivia Keiser,et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. , 2005, Journal of the National Cancer Institute.
[84] G. Ruiz-Palacios,et al. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses , 2006, AIDS research and therapy.
[85] N. Christensen,et al. Antibody-mediated neutralization in vivo of infectious papillomaviruses , 1990, Journal of virology.
[86] G. Hartmann,et al. Activation of Dendritic Cells and Induction of T Cell Responses by Hpv 16 L1/E7 Chimeric Virus-Like Particles are Enhanced by Cpg ODN or Sorbitol , 2004, Antiviral therapy.
[87] S. H. van der Burg,et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. , 2002, Vaccine.
[88] W. White,et al. In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16 , 1998, Journal of Virology.
[89] S. Piantadosi,et al. Spontaneous Regression of High-Grade Cervical Dysplasia: Effects of Human Papillomavirus Type and HLA Phenotype , 2005, Clinical Cancer Research.
[90] R. Schlegel,et al. HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions. , 1992, Virology.
[91] N. Christensen,et al. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. , 1991, Virology.
[92] D. Lowy,et al. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[93] D. DiMaio,et al. Rapid induction of senescence in human cervical carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[94] L. Koller,et al. Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts. , 1972, The Journal of investigative dermatology.
[95] S. Harrison,et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. , 2000, Molecular cell.
[96] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[97] D. Lowy,et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. , 2003, Journal of the National Cancer Institute.
[98] T. Rohan,et al. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. , 1999, Journal of the National Cancer Institute.
[99] M. Schiff,et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. , 2004, Vaccine.
[100] S. Marshall,et al. Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus , 2006, International journal of cancer.
[101] James P. Hughes,et al. The Theoretical Population-Level Impact of a Prophylactic Human Papilloma Virus Vaccine , 2002, Epidemiology.
[102] J. Dillner,et al. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. , 1995, Virology.
[103] Daron G Ferris,et al. Efficacy of a bivalent L 1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women : a randomised controlled trial , 2005 .
[104] R. Woods,et al. Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1 , 1999, Journal of Virology.
[105] Y. L. Lin,et al. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. , 1992, Virology.
[106] R. Steinbrook. The potential of human papillomavirus vaccines. , 2006, The New England journal of medicine.
[107] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[108] D. Lowy,et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[109] R. Curtiss,et al. Immunogenicity against Human Papillomavirus Type 16 Virus-Like Particles Is Strongly Enhanced by the PhoPc Phenotype in Salmonella enterica Serovar Typhimurium , 2004, Infection and Immunity.
[110] R. Roden,et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice , 1997, Infection and immunity.
[111] S. Franceschi,et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis , 2005, The Lancet.
[112] D. Lowy,et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection , 1995, Journal of virology.
[113] D. Lowy,et al. A quantitative in vitro focus assay for bovine papilloma virus. , 1980, Virology.
[114] M. Hagensee,et al. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins , 1993, Journal of virology.
[115] D. Lowy,et al. Interaction of papillomaviruses with the cell surface , 1994, Journal of virology.
[116] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.